Dilip Shanghvi Net Worth, Age, Family & Biography $18.5B Real Time Net Worth #110 in the world today

Avan Parvadiya — Tue, 18 Apr 2023 09:39:51 +0000

About Dilip Shanghvi

Dilip Shanghvi, a renowned entrepreneur hailing from Amreli, Gujarat, is widely recognized as one of India’s wealthiest individuals. He currently holds the position of Managing Director at Sun Pharmaceuticals, a multinational pharmaceutical corporation headquartered in Mumbai, India. Sun Pharmaceuticals has become a major player in the global pharmaceutical industry and one of the largest pharmaceutical companies in India under Shanghvi’s leadership.

Also, Shanghvi is well-known for his charitable efforts. He established the Shantilal Shanghvi Foundation 2015, which bears his father’s name, to support various social causes, education, and healthcare. Sun Pharmaceuticals has been successful as a result of Dilip Shanghvi’s entrepreneurial vision and business cleverness, making him one of India’s most influential business leaders.

Dilip Shanghvi’s Sun Pharma is today the largest company in pharma sector.

Dilip Shanghvi Career

Shanghvi started by assisting his father in his Kolkata-based wholesale dealership of mostly generic medicines. During this work, he considered producing his own drugs rather than selling those of others.
With a capital of INR 10,000, the 27-year-old Shanghvi finally opened his first manufacturing unit in 1982. Sun Pharmaceutical Industries was the name he gave his company.

The unit, which was in his home state of Gujarat and was just a short drive from Mumbai, only produced one psychiatry drug. However, Sun Pharma was able to acquire the American company Caraco Pharma by 1997 thanks to Shanghvi’s business acumen and drive. In 2007, Sun also bought Israel’s Taro Pharma. In 2012, Shanghvi resigned as chairman and CEO and appointed Israel Makov, formerly CEO of Teva Pharmaceuticals; Shanghvi was made director of management.

In April 2014, Sun, Ranbaxy, and Daiichi Sankyo agreed that Sun would take on $800 million in Ranbaxy debt and acquire all of Ranbaxy’s outstanding shares for $3.2 billion in Sun stock. Daiichi became Sun’s second-largest shareholder when the transaction closed in March 2015, making Sun India the world’s fifth-largest pharmaceutical company. He will continue to serve as a chairman and non-executive director of SPARC despite his resignation as managing director in May 2021.

Dilip Shanghvi Facts

India Today magazine ranked Dilip Shanghvi 8th on its list of India’s most influential people in 2017.

Founder and managing director of Sun Pharmaceuticals Dilip Shanghvi and Adam H Schechter President of Global Human Health and Executive Vice President at Merck & Co. during a press conference to announce the joint venture between the Merk & Co. and Sun Parma to develop and market generic drugs at Taj Mahal Hotel on April 11, 2011 in Mumbai, India.